India · Delayed Price · Currency is INR Rossari Biotech Statistics
Total Valuation
Rossari Biotech has a market cap or net worth of INR 24.71 billion. The enterprise value is 27.92 billion.
| Market Cap | 24.71B |
| Enterprise Value | 27.92B |
Important Dates
The next estimated earnings date is Friday, October 23, 2026.
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
Rossari Biotech has 55.39 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Current Share Class | 55.39M |
| Shares Outstanding | 55.39M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 53.47% |
| Owned by Institutions (%) | 17.19% |
| Float | 17.65M |
Valuation Ratios
The trailing PE ratio is 16.40 and the forward PE ratio is 15.56. Rossari Biotech's PEG ratio is 1.25.
| PE Ratio | 16.40 |
| Forward PE | 15.56 |
| PS Ratio | 0.97 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 37.98 |
| PEG Ratio | 1.25 |
Enterprise Valuation
| EV / Earnings | 18.53 |
| EV / Sales | 1.10 |
| EV / EBITDA | 10.04 |
| EV / EBIT | 14.20 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | -2.18 |
| Interest Coverage | 5.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 8.70% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 7.03% |
| Revenue Per Employee | 43.59M |
| Profits Per Employee | 2.58M |
| Employee Count | 585 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Rossari Biotech has paid 533.76 million in taxes.
| Income Tax | 533.76M |
| Effective Tax Rate | 26.15% |
Stock Price Statistics
The stock price has decreased by -29.28% in the last 52 weeks. The beta is 0.55, so Rossari Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -29.28% |
| 50-Day Moving Average | 500.65 |
| 200-Day Moving Average | 514.74 |
| Relative Strength Index (RSI) | 25.14 |
| Average Volume (20 Days) | 84,983 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rossari Biotech had revenue of INR 25.50 billion and earned 1.51 billion in profits. Earnings per share was 27.20.
| Revenue | 25.50B |
| Gross Profit | 7.53B |
| Operating Income | 1.95B |
| Pretax Income | 2.04B |
| Net Income | 1.51B |
| EBITDA | 2.67B |
| EBIT | 1.95B |
| Earnings Per Share (EPS) | 27.20 |
Balance Sheet
The company has 1.15 billion in cash and 4.36 billion in debt, with a net cash position of -3.21 billion or -57.97 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 4.36B |
| Net Cash | -3.21B |
| Net Cash Per Share | -57.97 |
| Equity (Book Value) | 13.33B |
| Book Value Per Share | 240.75 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 650.68 million and capital expenditures -2.65 billion, giving a free cash flow of -2.00 billion.
| Operating Cash Flow | 650.68M |
| Capital Expenditures | -2.65B |
| Depreciation & Amortization | 725.38M |
| Net Borrowing | 2.13B |
| Free Cash Flow | -2.00B |
| FCF Per Share | -36.04 |
Margins
Gross margin is 29.53%, with operating and profit margins of 7.64% and 5.91%.
| Gross Margin | 29.53% |
| Operating Margin | 7.64% |
| Pretax Margin | 8.00% |
| Profit Margin | 5.91% |
| EBITDA Margin | 10.49% |
| EBIT Margin | 7.64% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.11%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.11% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | 0.06% |
| Earnings Yield | 6.10% |
| FCF Yield | -8.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Rossari Biotech is 610.50, which is 36.27% higher than the current price. The consensus rating is "Buy".
| Price Target | 610.50 |
| Price Target Difference | 36.27% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |